Provided by Tiger Fintech (Singapore) Pte. Ltd.

Monte Rosa Therapeutics

12.32
+1.1810.59%
Pre-market: 12.330.0100+0.08%08:51 EDT
Volume:2.15M
Turnover:25.78M
Market Cap:760.88M
PE:41.88
High:12.44
Open:11.30
Low:11.26
Close:11.14
52wk High:12.44
52wk Low:3.50
Shares:61.76M
Float Shares:30.30M
Volume Ratio:2.56
T/O Rate:7.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.2942
EPS(LYR):-0.9836
ROE:9.81%
ROA:2.66%
PB:2.84
PE(LYR):-12.53

Loading ...

Monte Rosa Therapeutics Advances with MRT-8102: A Promising Phase 1 Study

TIPRANKS
·
14 hours ago

Guggenheim Sticks to Their Buy Rating for Monte Rosa Therapeutics (GLUE)

TIPRANKS
·
Oct 24

Monte Rosa Therapeutics Unveils Preclinical Data on MRT-6160 for Autoimmune Diseases

Reuters
·
Oct 24

Monte Rosa Therapeutics (GLUE) Gets a Buy from TD Cowen

TIPRANKS
·
Sep 16

LifeSci Capital Sticks to Their Buy Rating for Monte Rosa Therapeutics (GLUE)

TIPRANKS
·
Sep 16

Wedbush Raises Price Target on Monte Rosa Therapeutics to $19 From $17, Maintains Outperform Rating

MT Newswires Live
·
Sep 15

Monte Rosa’s Stock (GLUE) Skyrockets on $5.7B Deal with Novartis

TIPRANKS
·
Sep 15

Monte Rosa Therapeutics Inc : Wedbush Raises Target Price to $19 From $17

THOMSON REUTERS
·
Sep 15

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Ocugen, Union Pacific

Reuters
·
Sep 15

Monte Rosa Therapeutics Partners with Novartis for Immunology

TIPRANKS
·
Sep 15

Monte Rosa Therapeutics Inc. Unveils Presentation on Targeted Protein Degradation and Future Market Opportunities

Reuters
·
Sep 15

Monte Rosa Therapeutics Shares up 50.9% Premarket After $5.7 Billion Drug Development Deal With Novartis

THOMSON REUTERS
·
Sep 15

Novartis, Monte Rosa strike $5.7 billion drug development deal

Reuters
·
Sep 15

Monte Rosa Therapeutics and Novartis Ink $5.7 Billion Collaboration for Novel Degraders in Immune-mediated Diseases

Reuters
·
Sep 15

Monte Rosa Therapeutics Inc - to Receive $120 Mln Upfront, Eligible for Milestones

THOMSON REUTERS
·
Sep 15

Monte Rosa Therapeutics Announces Collaboration With Novartis for Degraders to Treat Immune-Mediated Diseases

THOMSON REUTERS
·
Sep 15

Monte Rosa Therapeutics Inc - Eligible for up to $5.7 Bln in Deal Value

THOMSON REUTERS
·
Sep 15

Monte Rosa Therapeutics Inc. to Participate in Morgan Stanley Annual Global Healthcare Conference

Reuters
·
Sep 02

Monte Rosa Therapeutics Q2 EPS $(0.15) Beats $(0.39) Estimate, Sales $23.19M Beat $10.80M Estimate

Benzinga
·
Aug 07

Monte Rosa Therapeutics Q2 Collaboration Revenue USD 23.194 Million

Reuters
·
Aug 07